The 2026 NFL season is the first without Mike Tomlin somewhere on the sidelines in decades.

And while the former Steelers coach has moved into the world of TV broadcasting, he's about to become a big deal in a corner of the internet no one would've expected a few months ago.

Visit tr-sport.bond for more information.

"Minecraft" streaming.

That's right, the longtime Steelers head coach is about to let fans into the blockified city he has been crafting for the last twelve years.

"It was therapeutic for me," Tomlin said in a video posted to social media. "It allowed me to detach from the pressures and the reality of life. Kind of my secret obsession, and so let's take you all through it."

The video then teased the release of a full video on Tomlin's YouTube channel, which showed an aerial view of a city that had a baseball field, streets, and even buildings with what looked to my eye to be HVAC equipment on the roof.

Mike means business, and I love it.

BREAKING UP TROY AIKMAN AND JOE BUCK WOULD BE A BIG MISTAKE FOR ESPN | BOBBY BURACK

The "NBC Sunday Night Football" analyst revealed in an interview around the start of the season that he was a big fan of the building game that has become a cultural phenomenon over the years.

It makes so much sense to me.

RAMS COACH SEAN MCVAY'S '60 MINUTES' INTERVIEW REVEALS WHY YOU SHOULDN'T FIND YOUR IDENTITY IN YOUR JOB

Being an NFL coach is such a high-pressure job with a lot of noise. How better to get a break from that than by focusing all of your attention on the 8-bit stadium you're trying to construct?

I can't think of one, and it's a pretty healthy way to tune everything out and get yourself focused on the present.

If you're wondering how he was able to handle being an NFL coach for so long, well, for twelve of those years, this is your answer.

Now that Tomlin isn't leading an NFL team anymore, he's got more time to devote to Tomlinburg (or whatever he calls it), and I expect it to be looking like Tokyo in a few months.

Read full story at source

Hyderabad-headquartered pharmaceutical giant Aurobindo Pharma Ltd announced that its US specialty subsidiary, Acrotech Biopharma Inc., has officially launched ADQUEY ointment across the United States.

The milestone that came on Wednesday marks the Indian healthcare major’s strategic entry into the lucrative American dermatology segment.

ADQUEY is a non-steroidal, topical phosphodiesterase-4 (PDE4) inhibitor specifically approved for the treatment of mild-to-moderate atopic dermatitis in adults and paediatric patients aged two years and older. The active molecule, difamilast, was originally discovered by Japan’s Otsuka Pharmaceutical and subsequently licensed to Acrotech for exclusive commercialisation within the US market.

Visit rouesnews.click for more information.

According to IQVIA MAT data, ADQUEY enters a highly competitive US therapeutic market segment estimated at approximately $1.3 billion for the 12 months ending July 2026.

Strategic transition into high-value branded specialty care

The commercial rollout aligns with Aurobindo Pharma’s overarching corporate strategy to expand beyond its legacy generic drug offerings, Active Pharmaceutical Ingredients (APIs) and biosimilars.

As one of India’s largest generic drugmakers and a leading supplier in the United States by prescription volume, Aurobindo is actively scaling up its portfolio of higher-value branded specialty pharmaceuticals to drive sustainable long-term revenue.

Acrotech Biopharma operates as a step-down subsidiary designed specifically as a commercialisation platform for innovative proprietary medicines.

The firm first established a presence in branded oncology back in 2019 after acquiring a portfolio of marketed haematology and oncology injectables from Spectrum Pharmaceuticals. Since then, Acrotech has steadily broadened its therapeutic footprint through targeted licensing deals, strategic acquisitions, and commercial partnerships.

Dedicated commercial infrastructure and market outlook

To ensure the successful rollout of ADQUEY and lay the foundation for future dermatology pipeline expansion, Acrotech has established a specialised, dedicated dermatology business unit.

This platform integrates cross-functional commercial capabilities spanning targeted marketing, specialised sales forces and field-based clinical engagement teams.

The new unit will prioritise driving clinical awareness among dermatology healthcare professionals, improving patient access and guiding individuals through their treatment journeys.

Simultaneously, the division is task-focused on building the operational infrastructure and commercial expertise required to support future specialty dermatology launches.

Commenting on the rollout, Ashish Anvekar, president of Acrotech Biopharma, noted that the launch of ADQUEY represents an essential milestone for the company by introducing a differentiated, non-steroidal treatment option for individuals living with atopic dermatitis.

He emphasised that the newly established dermatology platform is structured not only to maximise ADQUEY’s immediate impact, but also to build the long-term organisational capabilities needed to address broader unmet patient needs across dermatologic care.

Following the announcement, shares of parent company Aurobindo Pharma Ltd closed at Rs1,666.50 on the Bombay Stock Exchange (BSE) on Wednesday, down Rs36.50, or 2.14%, amid broader market movements.

Read full story at source